HAR6111: Methods and Processes in International Health Technology Assessment (online)
This module outlines the process of Health Technology Assessment and sets out the framework by which companies may develop Therapeutic Value Propositions (TVPs), i.e. positions in a disease management pathway where a new technology may add value in terms of effectiveness, safety or cost. The module covers identification and synthesis of evidence to construct disease management pathways, and how to pinpoint areas of unmet need. It also covers an introduction to the types of evidence needed to demonstrate clinical and cost-effectiveness, including clinical trial design as well as non-trial evidence.
This module aims to equip students with practical skills in synthesising evidence to construct disease management pathways; analytical skills in identifying therapeutic value propositions (TVPs), i.e. positions in the pathway where a new technology may be of value; and awareness of the different types of evidence (trial and non-trial) required to demonstrate value.
By the end of the module students will be able to:
- Outline the process of Health Technology Assessment to evaluate clinical and cost-effectiveness of a new technology
- Identify and synthesise evidence about a new technology and therapeutic area
- Construct disease management pathways to illustrate current management of a condition
- Identify therapeutic value propositions (TVPs), i.e. positions in the pathway where a new technology may be of value
- Use pathways and TVPs to determine the evidence needed to demonstrate clinical and cost-effectiveness, including clinical trials and non-trial evidence
Online materials, including texts, screencasts, and guided reading, will be used to define and illustrate the principles and key elements of the HTA process, therapeutic value propositions (TVPs), and disease management pathways and their role in reimbursement decisions.
Practical examples and exercises will be used to develop students' understanding of the HTA process, identifying and constructing pathways, developing TVPs, and identifying the evidence needed to support TVPs.
Independent study will be encouraged through the use of examples and exercises (as above), some of which include peer or tutor feedback to encourage and monitor participation and check understanding. Selected references for further reading will be provided within each section of the module. Students will be encouraged to us the Discussion Board for queries and discussion about course content with tutors and peers, and webinars with tutors and peers will be run during the module.
Independent Study (including preparation for assessments) 150 hours.
|Assignment (maximum 4000 words)||100%|
Assessment will be by assignment in which the student will produce a disease management pathway diagram, write a structured description of the pathway, define therapeutic value propositions (TVPs) for a new product, and describe the evidence required to demonstrate value for reimbursement.
The pass mark is 50%.